高脂血症合并高血压采用瑞舒伐他汀钙与阿托伐他汀钙治疗的临床效果报道

摘要

目的：：探讨高脂血症合并高血压采用瑞舒伐他汀钙与阿托伐他汀钙治疗的临床效果。方法：将在2014年1月~2015年1月期间收治的105例高脂血症合并高血压患者作为研究对象，将其依据治疗药物的不同分为甲组53例和乙组52例，甲组在口服氨氯地平治疗基础上应用瑞舒伐他汀钙治疗，乙组采取氨氯地平联合阿托伐他汀钙治疗，对比两组患者的血压、血脂水平的变化情况以及不良反应发生率。结果：治疗前，甲组与乙组的血压、血脂水平基本相同，其组间对比不具有统计学差异(均P>0.05)；治疗后，甲组患者的血压以及血脂控制水平均明显低于乙组。同时甲组患者不良反应发生率为5.66%，明显低于乙组的15.38%，其血压、血脂水平和不良发生率发生率的组间对比差异有统计学意义(均P<0.05)。结论：高脂血症合并高血压采用瑞舒伐他汀钙治疗的临床效果确切，可有效降低患者血压、血脂控制水平，且药物安全性较高，是高脂血症合并高血压患者的理想治疗药物。%Objective:To investigate the clinical effect of treating Hyperlipidemia and high blood pressure with rosuvastatin calcium and atorvastatin calcium.Methods:105 cases of hyperlipemia and high blood pres-sure treated in the community hospital from January 2014 to January 2015 were taken as the research object, who were divided into two groups(group A 53 cases and Groups B 52 cases in each group respectively)ac-cording to different drugs treatment.Group A were treated with rosuvastatin calcium after drinking amlodip-ine and Group B were treated with atorvastatin calcium and amlodipine.Then compare the blood pressure and blood lipid changes and adverse reaction incidence of the two groups.Results:Before treatment,the blood pressure and blood lipid level of group A and group B are basically the same,with no statistical difference (P>0.05);after treatment,the blood pressure and blood lipid level of group A were lower than those of group B.The incidence of adverse reactions in patients in group A was 5.66%,significantly lower than 15.38% in group B .The results of the two groups are of statistical significance (P<0.05).Conclusion:The clinical effect of treating Hyperlipidemia and high blood pressure with rosuvastatin calcium and atorvastatin calcium is exact,which can effectively reduce the blood pressure and blood lipid level,and of higher drug safety,is an ideal drug for treating patients with hyperlipidemia and high blood pressure.